The trial will be carried out through the National Cancer Institute at the National Institutes of Health (NIH). The company said that prior studies indicate hetIL-15 expands and
The approval allows for marketing of Opdivo in all 28 member states of the European Union (EU) and it follows an accelerated assessment by the European Medicines Agency’s
The company should now provide more information to NICE to make a final decision on the use of idelalisib in combination with rituximab for adults with chronic lymphocytic
The research collaboration will build on the company’s manufacturing protocol for its lead cancer program, CLBS20 (NBS20). All the parties will explore new techniques to further improve the
The Phase II Pathway Study’s primary efficacy outcome is the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal
The breakthrough therapy designation follows positive results from ARC001, which is the company’s randomized, double-blind, placebo-controlled Phase II trial of AR101 for desensitization treatment of peanut allergy. At
Glatopa is the first AP-rated substitutable generic designed to treat patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation
The company said that the time frame for FDA review is about 30 days. CLI is caused by reduced blood flow to the legs and about half of
The trial is designed to assess the role of edoxaban in VTE patients associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term
The company said that Zomig is the first nasal-delivered prescription medicine approved to treat acute migraine attacks in pediatric patients. The approval came after the FDA’s review of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.